The standard first-line treatment for around 80% of newly-diagnosed advanced non-small
cell lung cancer (NSCLC) is chemotherapy. Currently, patients are allocated to …

Preclinical evidence has been accumulating on the impact of the DNA repair status on the
sensitivity/resistance to anticancer agents in different tumor types, including lung cancer …

Platinum chemotherapeutic agents such as cisplatin are currently used in the treatment of
various malignancies such as lung cancer. However, their efficacy is significantly hindered …

Lung cancer is a worldwide epidemic and despite platinum-based chemotherapy being the
cornerstone of non-small cell lung cancer treatment, patient response rates to these …

Genetic variants in DNA repair genes may play a role in the effectiveness of platinum-based
chemotherapy in non-small cell lung cancer (NSCLC). We analyzed 17 SNPs in eight genes …

The results of cisplatin-based chemotherapy seem to have reached a plateau, and empirical
approaches are targeting the inclusion of novel biological agents with different mechanisms …

Drug therapy for non-small cell lung cancer consists mainly of platinum-based
chemotherapy regimens. However, toxicity, drug resistance, and high risk of death have …

Platinum compounds play a central role in cancer chemotherapy. Although treatment is
limited by side effects, they continue to have widespread application. One of the main aims …

The tumor genome is commonly aberrant as a consequence of mutagenic insult and
incomplete DNA repair. DNA repair as a therapeutic target has recently received …

Background In spite of the growing list of genetic abnormalities identified as being involved
in DNA repair pathways that alter chemosensitivity in non-small-cell lung cancer (NSCLC) …